|
|
| MRD / Regn No. |
: 20240000808 |
Date |
: 23/07/2026 |
| Patient Name |
: Vasanthalakshmi Narasimhan |
Age & Gender |
: 79 Yrs. / Female |
| Contact No. |
: 9500174447 |
UHID |
: |
| Ht / Wt / BMI |
: |
BP S / BP D |
: |
| Allergies |
: NKA |
Referred By |
: Chandru Sundaramurthy |
| |
|
| Problem
List |
: |
TYPE 2 DM (06/Aug/2004) | AV NODAL REENTRANT TACHYCARDIA (01/May/2024) | |
|
Subjective |
: |
HX OF PACEMAKER PLACEMENT,HX OF SUPPRESSED TSH,STARTED ON NMZ 5 MG,TYPE 2 DM FOR 20 YEARS,HAD AVNRT WITH CATHETER ABLATION,DRY SKIN |
|
Objective |
: |
THYROID NOT PALPABLE |
|
Analysis |
: |
TYPE 2 DM,AVNRT POST ABLATION,I131 GIVEN ON 14/3/2025 14 MCI,HYPOTHYROIDISM POST ABLATIVE,THYROTOXICOSIS RESOLVED,HYPOTHYROIDISM EUTHYROID ON MEDICATIONS,INCREASED LFT,TYPE 2 DM UNCONTROLLED,F4S0 FIBROSIS |
|
Plan |
: |
ADD SEMAGLUTIDE AND TZD,TO MEET GASTROENTEROLOGIST |
|
| Salient Investigations |
: |
URINE MICROALBUMINURIA: 14.6 mg/L | FUNDUS GLAUCOMA: NDR | FUNDUS MACULAR DEGENERATION: NAD | FUNDUS PHOTOGRAPH: NAD | OCULAR PRESSURE LEFT: 0.6 mmHg | OCULAR PRESSURE R: 0.4 mm HG | ABI LEFT: 1.0 | ABI RIGHT: 1.3 | ABI LEFT: 1.0 | ABI RIGHT: 1.3 | LIVER CAP: 200 dB/M | LIVER ELASTICITY: 2 kPA | LIVER METAVIR SCORE: F4 | LIVER STEATOSIS SCORE: S0 | |
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
TABLET THYROXINE 75 MCG
THYRONORM 75 MCG
Medicine For HYPOTHYROIDISM |
PO |
1-0-0 |
EMPTY STOMACH
|
TILL NEXT VISIT |
| MUST BE TAKEN ON AN EMPTY STOMACH. COFFEE TEA OR BREAKFAST MUST BE TAKEN ONLY AFTER 30 MINUTES. OTHER DRUGS CAN INTERFERE WITH THE ABSORPTION OF THYROXINE | |
|
2 |
INJECTION SEMAGLUTIDE 0.25 MG
OZEMPIC
Medicine For DM HEART KIDNEY PROTECTION |
SQ |
ONCE A WEEK |
AS DIRECTED NO RELATION TO FOOD
|
|
| MAY CAUSE NAUSEA OR VOMITING | |
|
3 |
PIOZ 7.5 MG
PIOGLITAZONE 7.5 MG |
|
1-0-0 |
BEFORE FOOD
|
TILL NEXT VISIT |
| MAY CAUSE SWELLING IN THE FEET | |
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: |
| Next Visit |
: 22/Aug/2026 |
| Tests Suggested For Next Visit |
: FBS 2HPP |
| |
|
| |
|
|
